keyword
MENU ▼
Read by QxMD icon Read
search

Esophagogastric cancer

keyword
https://www.readbyqxmd.com/read/29338535/different-lymph-node-staging-systems-for-patients-with-adenocarcinoma-of-esophagogastric-junction
#1
Zhangjian Zhou, Xin Xie, Nan Hao, Dongmei Diao, Yongchun Song, Peng Xia, Chengxue Dang, Hao Zhang
OBJECTIVE: In addition to the traditional TNM N staging system, lymph node ratio (LNR) and log odds of metastatic lymph nodes (LODDS) staging methods were developed in cancers. We aimed to examine their relative prognostic performance in patients with adenocarcinoma of esophagogastric junction (AEG). PATIENTS AND METHODS: Patients who underwent surgical resection for AEG were identified from the Surveillance, Epidemiology, and End Results (SEER) Program and the First Affiliated Hospital of Xi'an Jiaotong University as the training and validation sets, respectively...
January 17, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29313724/early-enteral-nutrition-is-associated-with-faster-post-esophagectomy-recovery-in-chinese-esophageal-cancer-patients-a-retrospective-cohort-study
#2
Hongyu Han, Meixia Pan, Yang Tao, Runzhong Liu, Zhiliang Huang, Korinne Piccolo, Caiyun Zhong, Ranyi Liu
We retrospectively examined a large cohort of esophageal carcinoma patients who received early enteral nutrition (EEN) to clarify the validity of EEN compared with total parenteral nutrition (TPN). Included were a total of 665 consecutive patients with histologically confirmed carcinoma of the esophagus or esophagogastric junction; and all patients underwent esophagectomy. The patients were divided into two groups: TPN (n = 262) and EEN (n = 403). The TPN group consisted of patients who only received intravenous nutrition support after operation...
January 9, 2018: Nutrition and Cancer
https://www.readbyqxmd.com/read/29285668/cabagast-multicentre-phase-ii-study-with-cabazitaxel-in-previously-treated-patients-with-advanced-or-metastatic-adenocarcinoma-of-the-esophagogastric-junction-and-stomach
#3
Harald Schmalenberg, Salah-Eddin Al-Batran, Claudia Pauligk, Thomas Zander, Alexander Reichart, Udo Lindig, Mathias Kleiß, Lothar Müller, Claus Bolling, Thomas Seufferlein, Peter Reichardt, Frank Kullmann, Henning Eschenburg, Alexander Schmittel, Matthias Egger, Andreas Block, Thorsten Oliver Goetze
INTRODUCTION: This is a single-arm study (NCT01956149) to determine the prolonged (≥ 4 months) disease control rate with cabazitaxel administered in second-(or later) setting for patients with advanced or metastatic adenocarcinoma of the esophagogastric junction (EGJ) and stomach. METHODS: 65 patients with advanced EGJ and stomach cancer were treated with 20 mg/m2 cabazitaxel every 3 weeks for a maximum of six cycles. The main objective of the study is a prolonged disease control rate (pDCR: CR, PR or SD lasting at least 4 months)...
December 28, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29282088/the-renaissance-aio-flot5-trial-effect-of-chemotherapy-alone-vs-chemotherapy-followed-by-surgical-resection-on-survival-and-quality-of-life-in-patients-with-limited-metastatic-adenocarcinoma-of-the-stomach-or-esophagogastric-junction-a-phase-iii-trial-of-the
#4
Salah-Eddin Al-Batran, Thorsten O Goetze, Daniel W Mueller, Arndt Vogel, Michael Winkler, Sylvie Lorenzen, Alexander Novotny, Claudia Pauligk, Nils Homann, Thomas Jungbluth, Christoph Reissfelder, Karel Caca, Steffen Retter, Eva Horndasch, Julia Gumpp, Claus Bolling, Karl-Hermann Fuchs, Wolfgang Blau, Winfried Padberg, Michael Pohl, Andreas Wunsch, Patrick Michl, Frank Mannes, Matthias Schwarzbach, Harald Schmalenberg, Michael Hohaus, Christian Scholz, Christoph Benckert, Jorge Riera Knorrenschild, Veit Kanngießer, Thomas Zander, Hakan Alakus, Ralf-Dieter Hofheinz, Claus Roedel, Manish A Shah, Mitsuru Sasako, Dietmar Lorenz, Jakob Izbicki, Wolf O Bechstein, Hauke Lang, Stefan P Moenig
BACKGROUND: Historical data indicate that surgical resection may benefit select patients with metastatic gastric and gastroesophageal junction cancer. However, randomized clinical trials are lacking. The current RENAISSANCE trial addresses the potential benefits of surgical intervention in gastric and gastroesophageal junction cancer with limited metastases. METHODS: This is a prospective, multicenter, randomized, investigator-initiated phase III trial. Previously untreated patients with limited metastatic stage (retroperitoneal lymph node metastases only or a maximum of one incurable organ site that is potentially resectable or locally controllable with or without retroperitoneal lymph nodes) receive 4 cycles of FLOT chemotherapy alone or with trastuzumab if Her2+...
December 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29279692/long-term-survival-of-a-patient-with-adenocarcinoma-of-the-esophagogastric-junction-with-a-portal-vein-tumor-thrombosis-who-underwent-palliative-total-gastrectomy-a-case-report
#5
Sung Don Oh, Sung Jin Oh, Byoung Jo Suh, Jin Yong Shin, Jong Kwon Park
Portal vein tumor thrombosis (PVTT) with advanced gastric cancer is very rare; when it occurs, it exhibits aggressive growth and carries a poor prognosis. In addition, definitive treatment has not been established due to insufficient data. Herein, we report a case of PVTT associated with an adenocarcinoma of the esophagogastric junction that was successfully controlled by means of a palliative total gastrectomy without surgical resection of the PVTT and administration of palliative continuous doxifluridine.
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29279556/lymphangiography-was-useful-in-postoperative-intractable-chylothorax-after-surgery-for-esophageal-cancer-a-case-report
#6
Takeshi Shimakawa, Yoshihiko Naritaka, Miki Miyazawa, Shinichi Asaka, Asako Shimazaki, Kentaro Yamaguchi, Hajime Yokomizo, Kazuhiko Yoshimatsu, Shunichi Shiozawa, Takao Katsube
Postoperative chylothorax after surgery for esophageal cancer is a rare but serious complication. Treatment initially consists of conservative therapy and, if it fails to provide improvement, it is important to perform surgical treatment without delay. We report on a recent case of intractable chylothorax. This report describes a 72-year-old man with Stage III esophageal squamous cell carcinoma. Subtotal esophagectomy, through a right thoracoabdominal approach with two-field lymphadenectomy, and cervical esophagogastric anastomosis via the retrosternal route, were performed...
2017: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/29243195/indication-for-endoscopic-treatment-based-on-the-risk-of-lymph-node-metastasis-in-patients-with-siewert-type-ii-iii-early-gastric-cancer
#7
Jeung Hui Pyo, Hyuk Lee, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Kyoung-Mee Kim, Heejin Yoo, Soohyun Ahn, Jae J Kim
BACKGROUND: Because of the poor prognosis of proximal gastric cancers, there is debate as to whether the conventional indications for endoscopic resection can be used. METHODS: Among subjects who underwent surgery for esophagogastric junction or gastric cardia cancer, 256 patients with T1 type II/III of the Siewert classification were included in this study. The association of lymph node metastasis (LNM) with each variable was analyzed using logistic regression models...
December 14, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/29230683/primary-esophagogastric-neuroendocrine-carcinoma-a-retrospective-study-from-the-nottingham-upper-gastrointestinal-cancer-center
#8
Constantinos Savva, Philip Kaye, Irshad Soomro, Simon L Parsons, Eleanor James, Srinivasan Madhusudan
No abstract text is available yet for this article.
December 11, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29224262/-discussion-of-n-staging-category-of-the-eighth-edition-of-the-ajcc-esophageal-cancer-staging-system
#9
W P Wang, Y S Yang, S L He, L Q Chen
AJCC Esophageal Cancer Staging System, 8(th) edition will be implemented on January 1, 2018. The N staging in 8(th) edition of staging system remains following 7(th) edition based on the number of metastatic nodes, except the limited revision of the regional lymph node map. N staging revision was reviewed from the simple definition of negative (N0) and positive (N1) lymph node(s) to the positive node number based proposal (7(th) edition). The 7(th) edition staging system, especially the N staging, were proved with more advantages on distinguishing disease progression and predicting prognosis of the esophageal cancer...
December 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/29221517/urban-rural-disparity-in-helicobacter-pylori-infection-related-upper-gastrointestinal-cancer-in-china-and-the-decreasing-trend-in-parallel-with-socioeconomic-development-and-urbanization-in-an-endemic-area
#10
Xiaoduo Wen, Denggui Wen, Yi Yang, Yuetong Chen, Guiying Wang, Baoen Shan
BACKGROUND: Globally China has the largest urban-rural disparity in socioeconomic development, and the urban-rural difference in upper gastrointestinal cancer (UGIC) is similar to the difference between developed and developing countries. OBJECTIVES: To describe urban-rural disparity in UGIC and to emphasize prevention by socioeconomic development and urbanization in China. METHODS: Age-standardized incidence rates (ASRs) of cancers in 2012 were compared between urban Shijiazhuang city and rural Shexian County, and trends from 2000-2015 in Shexian County were analyzed...
May 2017: Annals of Global Health
https://www.readbyqxmd.com/read/29177210/patients-unfit-for-neoadjuvant-therapy-may-still-undergo-resection-of-locally-advanced-esophageal-or-esophagogastric-junctional-cancer-with-acceptable-oncological-results
#11
J Robert O'Neill, Ewan D Kennedy, Vicki Save, Barbara Langdale-Brown, Lucy Wall, Richard J E Skipworth, Simon Paterson-Brown
Neoadjuvant chemotherapy (NA) is routinely offered to patients undergoing resection for locally advanced (≥cT3Nx or cTxN+) esophageal or esophagogastric junctional (EGJ) cancer in the United Kingdom. Patients with comorbidity precluding the use of NA can be considered for resection yet the effect of omitting NA on survival is unclear. Methods: Retrospective review of prospectively collected clinical data from patients undergoing attempted curative therapy for ≥cT3Nx or cTxN+ esophageal or EGJ (Siewert type I-III) cancer between 2001 and 2013...
February 2017: International Journal of Surgery. Oncology
https://www.readbyqxmd.com/read/29151938/comparison-of-her2-and-lauren-classification-between-biopsy-and-surgical-resection-samples-primary-and-metastatic-samples-of-gastric-cancer
#12
Miao-Zhen Qiu, Si-Mei Shi, Min Chen, Jing Wang, Qi-Nian Wu, Hui Sheng, Hui-Zhong Zhang, Jing-Ping Yun, Zhi-Wei Zhou, Feng-Hua Wang, Da-Jun Yang, Rui-Hua Xu
Purpose: Patients with advanced or metastatic adenocarcinoma of the stomach or esophagogastric junction for whom trastuzumab therapy is being considered, assessment for tumor human epidermal growth factor receptor-2 (HER2) status is necessary. Can the HER2 status and Lauren classification of the biopsy sample truly represent the HER2 status in the gastric cancer? Methods: Formalin-fixed, paraffin-embedded sections of 116 pair surgically resected and biopsy specimens as well as 80 pair primary and metastatic lesions of gastric cancer patients were analyzed...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29137409/overexpression-of-cten-relates-to-tumor-malignant-potential-and-poor-outcomes-of-adenocarcinoma-of-the-esophagogastric-junction
#13
Kenichi Aratani, Shuhei Komatsu, Daisuke Ichikawa, Takuma Ohashi, Mahito Miyamae, Wataru Okajima, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, Toshiyuki Kosuga, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Hitoshi Tsuda, Eigo Otsuji
Background: To detect a novel treatment target for adenocarcinoma of the esophagogastric junction (AEG), we tested whether C-terminal tensin-like (CTEN), a member of the tensin gene family and frequently overexpressed in various cancers, acts as a cancer-promoting gene through overexpression in AEG. Materials and Methods: We analyzed 5 gastric adenocarcinoma (GC) cell lines and 104 primary AEG tumors curatively resected in our hospital between 2000 and 2010. Results: CTEN overexpression was detected in GC cell lines (2/5 cell lines; 40%) and primary AEG tumor samples (35/104 cases; 34%)...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29129093/xxxxx
#14
Tomas G Lyons, Geoffrey Y Ku
The poor prognosis for patients with esophagogastric cancers (EGC) requires the development of newer more effective therapies to further improve the treatment outcomes for this disease. Immunotherapy is a novel treatment strategy that is dramatically changing the treatment landscape for several types of cancers. Cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death the programmed death (PD)-1/PD-ligand are essential immune checkpoint inhibitors that suppress T cell activation. Targeting of these immune checkpoints with monoclonal antibodies has shown clinical efficacy in several solid tumors which has led to their approval and use in routine clinical practice...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129089/systemic-therapy-for-esophageal-cancer-chemotherapy
#15
Geoffrey Y Ku
As one-half of patients with esophagogastric cancer (EGC) present with metastatic disease and the majority of patients with locally advanced disease will eventually develop metastatic disease despite multimodality therapy, most patients will receive palliative chemotherapy at some point. The reference first-line regimen consists of a fluoropyrimidine/platinum combination, which is the standard in East Asia, where this disease is endemic. Options include infusional 5-fluorouracil (5-FU), capecitabine, S-1 and other oral 5-FU pro-drugs and cisplatin or oxaliplatin...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29129088/systemic-therapy-for-esophagogastric-cancer-targeted-therapies
#16
Tomas G Lyons, Geoffrey Y Ku
The poor prognosis for patients with esophagogastric cancers (EGC) has resulted in an increased focus on the use of targeted agents in this disease. Targets include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), Her2, mammalian target of rapamycin (mTOR), MET, poly (ADP-ribose) polymerase (PARP) and claudin 18.2 (CLDN18.2). Trastuzumab, an anti-Her2 antibody, was approved by the U.S. FDA in 2010 as first-line therapy in combination with chemotherapy for Her2-positive disease...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29122777/genetic-predictors-of-response-to-systemic-therapy-in-esophagogastric-cancer
#17
Yelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K Chatila, Jaclyn F Hechtman, Geoffrey Y Ku, Jamie C Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier, Efsevia Vakiani, Jianjiong Gao, Zachary J Heins, Benjamin E Gross, David P Kelsen, Liying Zhang, Vivian E Strong, Mark Schattner, Hans Gerdes, Daniel G Coit, Manjit Bains, Zsofia K Stadler, Valerie W Rusch, David R Jones, Daniela Molena, Jinru Shia, Mark E Robson, Marinela Capanu, Sumit Middha, Ahmet Zehir, David M Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H Ilson, Michael F Berger, Laura Tang, Barry S Taylor, David B Solit, Nikolaus Schultz
The incidence of esophagogastric cancer is rapidly rising but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance, we implemented prospective tumor sequencing of metastatic esophagogastric cancer patients. There was no association between HRD defects and response to platinum-based chemotherapy. Patients with MSI-H tumors were intrinsically resistant to chemotherapy but more likely to achieve durable responses to immunotherapy...
November 9, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29102948/five-year-survival-after-surgical-removal-and-gamma-knife-stereotactic-radiosurgery-for-a-cerebellar-metastasis-from-an-esophagogastric-junction-cancer-a-case-report-and-literature-review
#18
Yoshikazu Kanazawa, Itsuo Fujita, Daisuke Kakinuma, Yuto Aoki, Hitoshi Kanno, Hiroki Arai, Kunihiko Matsuno, Tomohiro Shimoda, Takeshi Matsutani, Nobutoshi Hagiwara, Tsutomu Nomura, Takeshi Yamada, Shunji Kato, Zenya Naito, Hideaki Takasaki, Eiji Uchida
Brain metastases originating from esophageal or gastric cancer are rare, accounting for 2.1-3.3% of all brain tumors registered in Japan. There are no established therapeutic measures for brain metastases, which accordingly have a poor prognosis. We present here a patient who survived for 5 years after surgery and gamma knife treatment of a cerebellar metastasis from esophagogastric adenocarcinoma. The primary gastric cancer was treated by laparotomy with total gastrectomy, splenectomy, and D2 lymphadenectomy...
November 2017: In Vivo
https://www.readbyqxmd.com/read/29043568/intensified-neoadjuvant-multimodal-approach-in-synchronous-liver-metastases-from-gastric-cancer-a-single-institutional-experience
#19
REVIEW
L Ceniceros, A Chopitea, F Pardo, F Rotellar, L Arbea, J J Sola, J C Subtil, B Sangro, A Benito, J L Hernández-Lizoain, J Rodríguez
BACKGROUND: Synchronous liver metastases (LM) from gastric (GC) or esophagogastric junction (EGJ) adenocarcinoma are a rare events. Several trials have evaluated the role of liver surgery in this setting, but the impact of preoperative therapy remains undetermined. METHODS: Patients with synchronous LM from GC/EGJ adenocarcinoma who achieved disease control after induction chemotherapy (ICT) and were subsequently scheduled to chemoradiotherapy (CRT) to the primary tumor and surgery assessment were retrospectively analyzed...
October 17, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29026322/molecular-classification-of-esophagogastric-junction-carcinoma-correlated-with-prognosis
#20
Long Zou, Yinying Wu, Ke Ma, Yangwei Fan, Danfeng Dong, Ningyan Geng, Enxiao Li
A novel molecular classification of gastric cancer by the Asian Cancer Research Group (ACRG) is a potential advance in diagnosis and treatment, and it helps to determine prognosis. The use of immunohistochemistry (IHC) rather than gene expression analysis to determine tumor subtypes was evaluated with the aim of determining the feasibility of using the ACRG molecular classification. A total of 69 esophagogastric junction (EGJ) carcinomas were classified as microsatellite instable (MSI, 17.40%, 12 of 69), microsatellite stable with markers of epithelial-to-mesenchymal transition (MSS/EMT, 18...
2017: OncoTargets and Therapy
keyword
keyword
119338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"